RT Journal Article SR Electronic T1 Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1556 OP 1559 DO 10.2967/jnumed.115.166348 VO 57 IS 10 A1 Thorsten Derlin A1 Haefaa Alchalby A1 Peter Bannas A1 Azien Laqmani A1 Francis Ayuk A1 Ioanna Triviai A1 Hans-Heinrich Kreipe A1 Frank M. Bengel A1 Nicolaus Kröger YR 2016 UL http://jnm.snmjournals.org/content/57/10/1556.abstract AB Our objective was to assess the feasibility of 18F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis. Methods: Twelve patients with myelofibrosis underwent 18F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies. Results: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [CI], 0.54–1.0), a specificity of 0.83 (95% CI, 0.36–1.0), a negative predictive value of 1.0 (95% CI, 0.48–1.0), and a positive predictive value of 0.86 (95% CI, 0.42–1.0) for diagnosis of residual disease. Conclusion: 18F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.